Onco Actu du 7 juin 2018

	1.4 Biologie - Technos
Rosalind Franklin Institute will 'transform' life sciences research through disruptive technologies [University of Oxford] Business Secretary Greg Clark has today launched the £103m Rosalind Franklin Institute (RFI), a national centre of excellence that will harness disruptive technologies such as AI and robotics to improve dramatically our understanding of biology.
Scientists set out to build an ultra-fast camera to capture effect of new cancer drug tech [EndPoints] “We’re going to be building a camera that can capture the motion of these bubbles and how it’s pushing the drug deep into a tumor and hopefully once we’ve understood that process we can turn this into a new type of treatment,” says Professor Eleanor Stride in a film clip tied to the news.
	3.3 Prévention - Vaccins
American Cancer Society Launches Campaign to Eliminate Cervical Cancer [ACS] Mission: HPV Cancer Free aims to increase vaccination rates among boys and girls to 80%.
	4.12 Biopsies liquides
Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel To Accurately Diagnose Hepatocellular Carcinoma [Exact Sciences] The biomarker panel was shown to be 95 percent sensitive for detecting HCC across all stages. Sensitivity among patients with curable-stage disease was 91 percent. The panel has overall specificity of 93 percent, demonstrating its ability to discriminate between normal and diseased patients.
Exact Sciences, Mayo Clinic Share Data on DNA-Based Liver Cancer Test [Xconomy] The experimental test searches blood plasma for six biomarkers that are associated with HCC, and can discriminate between healthy and cancerous tissue. The biomarkers are able to do this by looking for methylated DNA—changes to the chemistry of DNA found in disease-ridden tissue, but not in normal tissue.
	5.1 Traitements - Pré-clinique
Stunting cell ‘antennae’ could make cancer drugs work again [Institute of Cancer Research] The researchers identified changes in cellular antennae known as cilia in different types of cancer cells with resistance to various types of drugs. That suggests that targeting cilia could be a universal way to resensitise cancers to treatment.
	5.10 Traitements - Essais
Most clinical trial participants find benefits of sharing personal data outweigh risks [Stanford Medicine] “Interestingly, nearly half our sample had experienced a breach of their personal data privacy in another context, yet they were still willing to share their clinical trial data,” she said.
Lessons on trial design and transparency from ClinicalTrials.gov [BMJ Blogs] For instance, oncology had the lowest rate of results publication across all disease areas, with only a fifth of all cancer studies published in a journal. Is this low rate because of the high prevalence of small sample sizes and non-randomised designs in this field? Or perhaps because of the fact that so many cancer trials fail to show positive outcomes? One thing is for certain: the evidence available in scientific literature is largely incomplete, and could be distorted as well.
	5.2.1 Pharma - Partenariats
BU and Johnson & Johnson Innovation Team Up to Fight Lung Cancer [Boston University] New Medical Campus center hopes to speed development of interventions and cures.
	5.3 Traitements - FDA, EMA, NICE...
FDA’s New Efforts to Advance Biotechnology Innovation [FDA] FDA is taking concrete and proactive steps to help ensure the safety of plant and animal biotechnology products, while promoting innovation and enhancing public and market confidence in FDA’s regulation of these products at home and abroad.
	5.3.4 Traitements - AMM (FDA, EMA,...)
US nod for Alimta/Keytruda lung cancer combo [PharmaTimes] The combination was approved via the US Food and Drug Administration’s accelerated approval pathway based on Phase II tumour response rate and progression-free survival (PFS) data observed in a cohort of Merck's KEYNOTE-021 study, and so its clinical benefit may still need to be verified in confirmatory trials.
	5.4 Traitements - Economie
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer [institute of Cancer Research] The Institute of Cancer Research (ICR) is calling for urgent discussions around the data supporting the drug’s effectiveness earlier in treatment and its price, and is urging a review of the decision within a year as new trial data become available.
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer [PharmaTimes] The National Institute for Health and Care Excellence has published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic model “did not accurately reflect the treatment pathway” for these patients.
Prostate cancer victims denied 'game-changing' drug [The Telegraph] New guidance from the National Institute for Health and Care Excellence rules that the drug abiraterone, which can extend survival by up to 15 months, cannot be offered before standard therapy.
Lung cancer immunotherapy drug approved for England [Cancer Research UK] Pembrolizumab (Keytruda) had been deemed too expensive to be routinely available according to rules recently introduced by NHS England. But an agreement has been made with the manufacturer to reduce the cost.
	5.5.15 ASCO (biopsies liquides)
Questions about a ‘simple blood test’ to screen for cancer prompt revealing answer: It’s complicated [HealthNewsReview] Goodman then asked how Oxnard envisioned the “blood test” being used. The researcher attempted to clarify: “This is not a blood test. This is a sequencing method that needs to be turned into a diagnostic.” The journalist asked if the words “simple blood test” used in the news release were misleading. Oxnard responded: “It has the potential to be a simple blood test.”
	5.5.4.5 ASCO (immunothérapies-CAR-T, thérapies cellulaires)
A watershed in fighting cancer – but a miracle cure is a long way off | Charles Swanton [The Guardian] The techniques used by Dr Steve Rosenberg’s team at the US National Cancer Institute, and which many of us in the UK (including my own team) are also working on, are fearsomely complex, and currently far outside the routine clinical reality of an NHS cancer centre.
	6.11 Patients
A Biotech Executive Faces End-Stage Cancer As A Patient [Forbes] For years, Michael Becker was one of the drug executives navigating swarms of cancer doctors at the annual meeting of American Society of Clinical Oncology, where 40,000 people gather every year to talk about the hottest cancer-killing drugs. This year he came back, but it was very different. This time he spoke to an audience of drug executives as a patient living on borrowed time.
	6.7 DMP, Big Data & applis
Clinical trial disruptor Science 37 in talks with SoftBank on a $150M investment — Recode [EndPoints] Using new telemedicine tech, they say they can accumulate clean datasets to show whether or not new drugs are working — hoping to disrupt the big players who now dominate the CRO world.
	6.7.3 DMP
Realizing the clinical potential of electronic health records [Stanford Medicine] Featuring panel discussions and small-group problem-solving sessions, the daylong symposium touched on improving inefficiencies of EHRs, harnessing data for population health management, building on successes and overcoming obstacles.